Showing 8421-8430 of 9737 results for "".
- Revance Therapeutics Initiates BELMONT Phase 2 Active Comparator Trial of Injectable RT002https://practicaldermatology.com/news/revance-launches-phase-2-belmont-study/2459035/Specialty biopharmaceutical company Revance Therapeutics, Inc. has initiated the BELMONT trial, a Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and
- Alcohol Intake Not Linked to Early BCChttps://practicaldermatology.com/news/alcohol-intake-not-linked-to-early-bcc/2459036/Despite some trends suggesting that high alcohol use and high UV exposure may be associated with risk for early onset BCC in women, there is no statistically significant association between lifetime alcohol intake and early-onset BCC overall or in women only, new data from the
- Chromogenex Releases Regenlite Transformhttps://practicaldermatology.com/news/chromogenex-releases-regenlite-transform/2459042/The latest addition to the Chromogenex family, Regenlite Transform is now available. It is specifically designed for managing inflammatory skin conditions without any discomfort, downtime or residual cell necrosis, the company says. A pure 585nm laser offers 300% more absorption in Oxyhae
- L'oreal USA Announces Changes In Leadership Within Active Cosmetics Divisionhttps://practicaldermatology.com/news/loreal-usa-announces-changes-in-leadership-within-active-cosmetics-division/2459045/Marc Toulemonde was appointed President of the Active Cosmetics Division of L’Oreal USA. In this role, Mr. Toulemonde will work on the SkinCeuticals, La Roche-Posay, Dermablend, and Vichy brands in the United States. Mr. Toulemonde brings expertise to the role from his m
- Pierre Fabre Dermatologie Receives the Prix Galien Award for Pharmaceutical Research for Hemangiolhttps://practicaldermatology.com/news/pierre-fabre-dermatologie-receives-the-prix-galien-award-for-pharmaceutical-research-for-hemangiol/2459047/Pierre Fabre Dermatologie, a subsidiary of Pierre Fabre Dermo-Cosmetics, was distinguished by the Prix Galien award (France) for Hemangiol, an oral pediatric propranolol solution specifically developed for some severe infantile hemangiomas. Hemangiol® was successively approved by Americ
- The Cetaphil Brand Launches New Cetaphil Baby Linehttps://practicaldermatology.com/news/the-cetaphil-brand-launches-new-cetaphil-baby-line/2459050/Galderma Laboratories, L.P., makers of Cetaphil, launched Cetaphil Baby, a line designed with babies and parents in mind. Cetaphil Baby is formulated with ingredients like organic calendula, almond oil and sunflower oil to soothe sensitive and irritated skin. All Cetaphil Baby products are
- PV-10 Data Published; Phase 3 Protocol Publishedhttps://practicaldermatology.com/news/20141121-pv-10_data_published_phase_3_protocol_published/2459054/Phase II data for PV-10 (Provectus Biopharmaceuticals, Inc.), presented at scientific meetings this fall, were published in Annals of Surgical Oncology in October. In the 80-subject study, the best overall response rate for target lesions was 51 percent, and the complete response rate was 26 percent
- Valeant Comments On Allergan Announcementhttps://practicaldermatology.com/news/20141117-valeant_comments_on_allergan_announcement/2459060/Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock. "We have seen the annou
- Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenuehttps://practicaldermatology.com/news/20141117-actavis_to_acquire_allergan_to_create_top_10_global_growth_pharmaceutical_company_with_23_billion_in_revenue/2459062/Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of A
- Zeltiq Named Top Medical Devices Company in Deloitte's Technology Fast 500™https://practicaldermatology.com/news/20141117-zeltiq_named_top_medical_devices_company_in__deloittes_technology_fast_500/2459063/Ranked among the top 25 companies in Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America, Zeltiq Aesthetics, Inc. is the top ranked